Published May 2010
| Version v1
Journal article
Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients' point of view
Contributors
Others:
- Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD) ; Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Centre de Recherche Cultures, Santé, Sociétés (JE 2424) (CReCSS) ; Université Paul Cézanne - Aix-Marseille 3-JE2424
- Institut Paoli-Calmettes ; Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)
- Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL) ; UNICANCER-Université Côte d'Azur (UCA)
- This research was funded by a grant from the Institut National du Cancer (INCa) and Conseil Régional Paca.
Description
Objective: The aim of this study on primary breast cancer patients undergoing adjuvant tamoxifen treatment was to determine how their perceptions of the treatment and their experience of side-effects contributed to their adherence to the treatment. Methods: A consecutive series of primary breast cancer patients eligible for tamoxifen therapy were studied qualitatively by conducting semi-structured in-depth interviews at two French cancer centres. Results: The women aged 35-65 (N 5 34) were struggling with several issues involving their understanding and experience of the treatment, which have not been documented so far. These issues included confusion about the 'hormonal' nature and activity of tamoxifen and the etiology of the changes in their menopausal status, as well as the symbolic associations formed by patients about the paradox of taking a treatment that has aging effects but saves lives. Conclusions: This study shows the great physical burden often associated with tamoxifen treatment and brings to light women's own complex representations of the treatment and their interpretation of the side-effects. Better communication between health-care providers and patients should ultimately help to prevent refusal or discontinuation of tamoxifen treatment.
Abstract
International audienceAdditional details
Identifiers
- URL
- https://www.hal.inserm.fr/inserm-02273146
- URN
- urn:oai:HAL:inserm-02273146v1
Origin repository
- Origin repository
- UNICA